Abstract
Deep learning models like the Lung Cancer Prediction Convolutional Neural Network (LCP CNN) have shown promise in stratifying indeterminate pulmonary nodules (IPNs). However, these models typically rely on single-timepoint snapshots, ignoring the longitudinal data often available in clinical practice. This study investigated whether tracking the change in LCP CNN scores over time improves malignancy prediction. Using a prospective-specimen collection, retrospective-blinded-evaluation (PRoBE) design, 80 subjects with IPNs (48 benign, 32 malignant) were analyzed across at least three consecutive CT scans. While initial LCP CNN scores showed no significant difference between groups, longitudinal trends diverged sharply: benign nodules remained stable, while malignant nodules showed a significant increase ($p < 0.001$). A joint model incorporating both score value and slope achieved a time-dependent AUC of 0.857, outperforming snapshot-based models. These findings suggest that longitudinal radiomic modeling can significantly enhance lung cancer risk assessment.
Introduction
Approximately 1.6 million indeterminate pulmonary nodules (IPNs) are detected annually in the United States. While the majority are benign, the clinical challenge lies in accurately identifying the small percentage of malignancies without subjecting patients to unnecessary, invasive biopsies. Current AI tools, such as the FDA-cleared Optellum LCP CNN, provide a malignancy probability score based on a single scan. However, radiologists traditionally rely on temporal changes—such as growth or morphological shifts—to manage nodules. This study bridges the gap between static AI snapshots and longitudinal clinical practice by evaluating the predictive power of AI score trajectories.
Methodology
The study utilized the Optellum LCP CNN model, which generates a malignancy score from 0 to 100. Researchers applied a "PRoBE" design to a cohort of 80 patients from Vanderbilt University Medical Center and the Nashville VA. Inclusion criteria required nodules between 6–30 mm and a minimum of three consecutive CT scans with a slice thickness of ≤ 1.5 mm.
To analyze the temporal data, the team developed a joint model for longitudinal and time-to-event data. They compared four predictive approaches:
- Last value: The most recent AI score only.
- Value: The full longitudinal history.
- Slope: The rate of score change.
- Value + Slope: A combined metric of current risk and trajectory.
Results and Key Insights
Divergent Trajectories
The most significant finding was the clear divergence in score trends between benign and malignant nodules. While individual trajectories can be noisy, the aggregate data revealed that benign nodules typically "flatline" or regress, whereas malignant nodules exhibit a consistent upward "climb" in risk scores.
Interestingly, the initial LCP CNN scores were not statistically different between the two groups. This suggests that a single baseline scan may be insufficient for definitive risk stratification, whereas the "delta" (change over time) provides a critical diagnostic signal. The difference in trends was highly significant (difference = 0.111, $p < 0.001$).
Predictive Performance
The joint "Value + Slope" model demonstrated superior predictive power compared to snapshot evaluations. When predicting malignancy 12 months into the future (using 24 months of prior data), the longitudinal model achieved a time-dependent AUC of 0.857, compared to 0.757 for the model using only the most recent score.
Discussion and Clinical Implications
By quantifying morphological changes that may be too subtle for human detection via standard RECIST measurements, longitudinal AI modeling offers a path toward "dynamic risk" assessment. Clinicians could potentially update a patient's probability of cancer with every new scan, allowing for earlier intervention in cases with rising trajectories and reducing the frequency of biopsies for stable, benign nodules.
While this pilot study is limited by a small sample size (n=80) and retrospective design, it provides a strong proof-of-concept for integrating temporal AI data into clinical workflows. Future work will focus on validating these findings in larger, external cohorts and comparing AI-driven score trends directly against traditional volumetric growth measurements.
Summary updated